Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Botta, S.
Investigations on the role of eIF2B5 in aggressive B-cell lymphoma.
[ Diplomarbeit/Master Thesis (UNI) ] Graz University of Technology; 2020. pp.42.
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Deutsch Alexander
- Feichtinger Julia
- Altmetrics:
- Abstract:
- Diffuse large B-cell lymphoma (DLBCL) is the most common subtype, accounting for 30-40% of all lymphomas in adults. With standard chemotherapy, aggressive B-cell lymphoma, even at the advanced stage, is in many instances a curable disease. Despite improvements in therapy, approximately one third of patients with advanced-stage DLBCL are still refractory to therapy or relapse. Experiments from my research group demonstrated that the eukaryotic initiation factor eIF2B5 was highly expressed in DLBCL and that its over-expression was associated with poor cancer-specific survival. The aim of this study was to determine the function of eIF2B5 in aggressive lymphoma cells in vitro. This was performed by lentiviral gene transfer to ectopically express eIF2B5 in aggressive lymphoma cells, followed by a cell growth assay as well as cell cycle analysis. Over-expression of eIF2B5 in aggressive lymphoma cells was a consequence for enhanced cell growth compared to negative vector controls. Furthermore, cell cycle analysis revealed that ectopic expression of eIF2B5 resulted in an increased propor-tion of proliferation cells. Overall, the data suggest that eIF2B5 possesses a proliferative as well as pro-survival function in aggressive lymphoma and that it significantly impacts on lymphomagenesis. Furthermore, the results support the hypothesis of my research group that eIF2B5 functions as an oncogene in aggressive lymphoma and thus may serve as an interesting therapeutic target.